Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Did You Know Previous | All Articles This Week | Next
This article originally posted 21 May, 2010 and appeared in  Issue 522

Glitazone Preserves Beta Cell Function by 70%

Glitazone Preserves Beta Cell Function by 70%: In patients with insulin resistance but near-normal glycated hemoglobin levels, pioglitazone (Actos) treatment cut the rate of progression to full-blown Type 2 diabetes by 70% relative to placebo, according to updated results from the ACT NOW study. See this week's Item #6.
Advertisement
Advertisement

 

Bookmark and Share | Print | Category | Home

This article originally posted 21 May, 2010 and appeared in  Issue 522

Past five issues: Diabetes Clinical Mastery Series Issue 85 | Issue 626 | Special Edition - Getting Patients on Track | Diabetes Clinical Mastery Series Issue 84 | Issue 625 |

 
Diabetes In Control Advertisers
 
 
Cast Your Vote
Now that once-weekly GLP-1 is available, which product are you recommending for your type 2 patients?

Navigate Diabetes In Control

Cardiovascular CE & CME Clinical Slides Drugs Affecting BG Safety Tools Test Your Knowledge Medications Polls Obesity Case Studies Jobs Interviews GLP-1 Agonist Sheri R. Colberg, PhD

Announcement:
 

Free Weekly Newsletter
Sign up here.

Free CE Available
CE Programs on diabetes

Search Articles On Diabetes In Control